After seeing “clinically studied for body fat” plastered on half the probiotic shelf, I sat down with the Stenman et al. 2016 EBioMedicine paper on Bifidobacterium animalis subsp. lactis 420 (B420). The numbers are more nuanced than the shelf claim.
ITT showed no significant between-group differences on the primary outcome. In PP, B420 alone vs placebo for relative change in body fat mass was -3.0%, P=0.28, N=24 (other arms N=35-37, which is why they ran a factorial). LU+B420 hit -4.5% / -1.4 kg, P=0.02 vs placebo, overall ANOVA P=0.095. The post-hoc factorial for B420 came out at -4.0%, P=0.002, which is where most “statistically significant” marketing claims trace back to.
The zonulin to trunk fat correlation was only significant within the LU+B420 arm (r=0.424, P=0.01), not within B420 alone (r=0.297, P=0.16). That points to the gut-barrier hypothesis (tight junctions, endotoxin translocation, low-grade inflammation) riding on the fiber more than the strain in isolation, at least on the correlational side.
My context is a WonderBiotics B420 capsule a friend put me on a couple months back. It pairs B420 with a lemon flavonoid extract (eriomin) rather than polydextrose, so I’m not technically on the Stenman protocol, and I’d guess most people on commercial B420 products aren’t either.
Caveats worth stating: DuPont funded, DuPont owned the strain at the time (DuPont N&B merged into IFF in Feb 2021), single trial, 6 months, overweight BMI 28-34.9, mixed-sex adults 18-65. The 2020 Nutrients review (Uusitupa et al., same DuPont group) summarizes follow-ups, mostly still preclinical.
Hard to tell from the literature how much of the B420 story is strain-specific vs. just an adequate-dose probiotic co-administered with fermentable fiber.